News Image

Despite its growth, NASDAQ:CORT remains within the realm of affordability.

By Mill Chart

Last update: Oct 20, 2023

Our stock screening tool has pinpointed CORCEPT THERAPEUTICS INC (NASDAQ:CORT) as a growth stock that isn't overvalued. NASDAQ:CORT is excelling in various growth indicators while maintaining a solid financial footing. Furthermore, it remains attractively priced. Let's delve into the specifics below.

Deciphering NASDAQ:CORT's Growth Rating

A key component of ChartMill's stock assessment is the Growth Rating, which spans from 0 to 10. This rating evaluates diverse growth factors, such as EPS and revenue growth, considering both past performance and future projections. NASDAQ:CORT has received a 7 out of 10:

  • CORT shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 15.94% yearly.
  • Looking at the last year, CORT shows a quite strong growth in Revenue. The Revenue has grown by 9.22% in the last year.
  • Measured over the past years, CORT shows a very strong growth in Revenue. The Revenue has been growing by 20.34% on average per year.
  • Based on estimates for the next years, CORT will show a very strong growth in Earnings Per Share. The EPS will grow by 20.15% on average per year.
  • The Revenue is expected to grow by 13.52% on average over the next years. This is quite good.
  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.

Valuation Analysis for NASDAQ:CORT

To assess a stock's valuation, ChartMill utilizes a Valuation Rating on a scale of 0 to 10. This comprehensive assessment considers various valuation aspects, comparing price to earnings and cash flows, while factoring in profitability and growth. NASDAQ:CORT has achieved a 5 out of 10:

  • 80.38% of the companies in the same industry are more expensive than CORT, based on the Price/Earnings ratio.
  • 77.51% of the companies in the same industry are more expensive than CORT, based on the Price/Forward Earnings ratio.
  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CORT indicates a somewhat cheap valuation: CORT is cheaper than 79.43% of the companies listed in the same industry.
  • Based on the Price/Free Cash Flow ratio, CORT is valued cheaply inside the industry as 87.08% of the companies are valued more expensively.
  • The excellent profitability rating of CORT may justify a higher PE ratio.
  • A more expensive valuation may be justified as CORT's earnings are expected to grow with 15.62% in the coming years.

Assessing Health Metrics for NASDAQ:CORT

ChartMill utilizes a Health Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of liquidity and solvency ratios, both in absolute terms and in comparison to industry peers. NASDAQ:CORT has earned a 8 out of 10:

  • An Altman-Z score of 19.85 indicates that CORT is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of CORT (19.85) is better than 93.78% of its industry peers.
  • CORT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
  • CORT has a Current Ratio of 4.65. This indicates that CORT is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 4.65, CORT is in the better half of the industry, outperforming 60.29% of the companies in the same industry.
  • CORT has a Quick Ratio of 4.57. This indicates that CORT is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of CORT (4.57) is better than 60.77% of its industry peers.

A Closer Look at Profitability for NASDAQ:CORT

ChartMill employs its own Profitability Rating system for stock evaluation. This score, ranging from 0 to 10, is derived from an analysis of diverse profitability metrics and margins. In the case of NASDAQ:CORT, the assigned 8 is noteworthy for profitability:

  • With an excellent Return On Assets value of 18.03%, CORT belongs to the best of the industry, outperforming 93.78% of the companies in the same industry.
  • With an excellent Return On Equity value of 22.44%, CORT belongs to the best of the industry, outperforming 92.34% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 20.31%, CORT belongs to the top of the industry, outperforming 95.69% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for CORT is significantly above the industry average of 15.23%.
  • CORT has a Profit Margin of 22.10%. This is amongst the best in the industry. CORT outperforms 93.78% of its industry peers.
  • The Operating Margin of CORT (23.09%) is better than 90.43% of its industry peers.
  • Looking at the Gross Margin, with a value of 98.65%, CORT belongs to the top of the industry, outperforming 97.61% of the companies in the same industry.

More Affordable Growth stocks can be found in our Affordable Growth screener.

Check the latest full fundamental report of CORT for a complete fundamental analysis.

Keep in mind

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.

Back

CORCEPT THERAPEUTICS INC

NASDAQ:CORT (4/25/2024, 7:00:00 PM)

After market: 22.21 0 (0%)

22.21

-0.27 (-1.2%)

CORT News

News Imagea day ago - Corcept Therapeutics IncorporatedCorcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
News Imagea day ago - Corcept Therapeutics IncorporatedCorcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

MENLO PARK, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter...

News Image3 days ago - Market News VideoNotable Monday Option Activity: RIOT, SIG, CORT
News Image4 days ago - Corcept Therapeutics IncorporatedCorcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
News Image7 days ago - ChartmillWhile growth is established for NASDAQ:CORT, the stock's valuation remains reasonable.

For those who appreciate growth without the sticker shock, CORCEPT THERAPEUTICS INC (NASDAQ:CORT) is worth considering.

News Image11 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
News Image11 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)

MENLO PARK, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...

News Image18 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
News Image25 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome
News Image25 days ago - Corcept Therapeutics IncorporatedCorcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome

MENLO PARK, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the...

News Imagea month ago - Market News VideoNotable Monday Option Activity: GME, LULU, CORT
News Image2 months ago - Seeking AlphaCorcept Therapeutics GAAP EPS of $0.28 beats by $0.02, revenue of $135.4M beats by $6.1M (NASDAQ:CORT)

Corcept Therapeutics reports Q4 2023 financial results, with GAAP EPS of $0.28 beating expectations by $0.02 and revenue of $135.4M surpassing estimates by...

CORT Links
Follow us for more